Who
Noah L. Rosenberg
Cmo
Company insider
Files Form 4 as: Cmo, Verrica Pharmaceuticals; Chief Medical Officer, Travere Therapeutics; Chief Medical Officer, Esperion Therapeutics.
In numbers
- Trades disclosed
- 44
- Buys
- 3
- Sells
- 15
- Bought
- $71K
- Sold
- $367K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 23 Jul 2013
- Last trade
- 18 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 18 Aug 2026 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $9,9882,030 at $4.92 | filing |
| 18 Aug 2026filed 18 Aug 2026 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $9,9882,030 at $4.92 | filing |
| 17 Aug 2026filed 18 Aug 2026 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $21K4,200 at $4.91 | filing |
| 17 Aug 2026filed 18 Aug 2026 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $21K4,200 at $4.91 | filing |
| 5 Jun 2026filed 9 Jun 2026 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —233,840 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —233,840 at $0.00 | filing |
| 25 Nov 2025filed 25 Nov 2025 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —589 | filing |
| 25 Nov 2025filed 25 Nov 2025 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $9,9942,357 at $4.24 | filing |
| 24 Mar 2025filed 26 Mar 2025 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —325,000 at $0.00 | filing |
| 17 Aug 2021filed 17 Aug 2021 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $24K1,407 at $17.12 | filing |
| 13 Aug 2021filed 17 Aug 2021 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,500 at $0.00 | filing |
| 28 Jul 2021filed 29 Jul 2021 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K1,250 at $13.81 | filing |
| 12 May 2021filed 13 May 2021 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,298375 at $19.46 | filing |
| 11 May 2021filed 13 May 2021 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,178375 at $19.14 | filing |
| 8 Feb 2021filed 9 Feb 2021 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $36K1,125 at $31.58 | filing |
| 5 Feb 2021filed 9 Feb 2021 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $35K1,125 at $31.41 | filing |
| 3 Feb 2021filed 5 Feb 2021 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,500 at $0.00 | filing |
| 3 Feb 2021filed 3 Feb 2021 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $36K1,250 at $28.91 | filing |
| 3 Feb 2021filed 3 Feb 2021 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K563 at $28.91 | filing |
| 2 Feb 2021filed 2 Feb 2021 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $38K1,250 at $30.75 | filing |
News
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit FacilityVRCA · manilatimes.net · 22 Oct 2026
0 headlines in the last 90 days name Noah L. Rosenberg; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.